Rebiotix Seeks $10M in Funding Round

The company is developing treatments for gastrointestinal issues that use human gut bacteria.

Biotech company Rebiotix Inc. is seeking $10 million in debt financing and convertible promissory notes, according to a Tuesday filing with the federal Securities and Exchange Commission.
The Roseville-based company is creating new treatments for gastrointestinal diseases that transplant healthy gut microbes into patients. Ailments they’re attempting to treat—or could study for treatment in the future—include Clostridium difficile (C. diff), inflammatory bowel disease/ulcerative colitis, hepatic encephalopathy and multi-drug resistant infections.
The company was founded in 2011 and is led by Lee Jones. Her resume includes stints at Medtronic, Inlet Medical and the Schulze Diabetes Institute at the University of Minnesota.
In its SEC filing, Rebiotix said it had raised over $8.5 million from 29 investors since it opened the financing round in late August.